RU2604062C2 - ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 - Google Patents

ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 Download PDF

Info

Publication number
RU2604062C2
RU2604062C2 RU2013103539/04A RU2013103539A RU2604062C2 RU 2604062 C2 RU2604062 C2 RU 2604062C2 RU 2013103539/04 A RU2013103539/04 A RU 2013103539/04A RU 2013103539 A RU2013103539 A RU 2013103539A RU 2604062 C2 RU2604062 C2 RU 2604062C2
Authority
RU
Russia
Prior art keywords
hydroxy
phenyl
chloro
amide
amino
Prior art date
Application number
RU2013103539/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2013103539A (ru
Inventor
Нидхи АРОРА
Шаоцин ЧЭНЬ
Йоханнес Корнелиус ГЕРМАНН
Андреас КУГЛЬСТАТТЕР
Шарада Шенви ЛАБАДИ
Клара Йеу Йен ЛИН
Мэтью К. ЛУКАС
Эми Джеральдин МОР
Ева ПАПП
Франсиско Ксавьер ТАЛАМАС
Ютта ВАННЕР
Цзаньшэн ЧЖАЙ
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2013103539A publication Critical patent/RU2013103539A/ru
Application granted granted Critical
Publication of RU2604062C2 publication Critical patent/RU2604062C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2013103539/04A 2010-07-13 2011-07-08 ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 RU2604062C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36385510P 2010-07-13 2010-07-13
US61/363,855 2010-07-13
US201161485145P 2011-05-12 2011-05-12
US61/485,145 2011-05-12
PCT/EP2011/061598 WO2012007375A1 (en) 2010-07-13 2011-07-08 Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators

Publications (2)

Publication Number Publication Date
RU2013103539A RU2013103539A (ru) 2014-08-20
RU2604062C2 true RU2604062C2 (ru) 2016-12-10

Family

ID=45467432

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013103539/04A RU2604062C2 (ru) 2010-07-13 2011-07-08 ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4

Country Status (11)

Country Link
US (4) US20120015962A1 (enExample)
EP (2) EP3252054A1 (enExample)
JP (3) JP5985473B2 (enExample)
KR (2) KR101995013B1 (enExample)
CN (3) CN110003219A (enExample)
AR (1) AR082154A1 (enExample)
BR (1) BR112013000868A2 (enExample)
CA (1) CA2802641C (enExample)
MX (2) MX340490B (enExample)
RU (1) RU2604062C2 (enExample)
WO (1) WO2012007375A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072599B2 (en) 2017-02-01 2021-07-27 Biotheryx, Inc. Pyrazole compounds and uses thereof
RU2770835C1 (ru) * 2018-08-27 2022-04-22 Шэньчжэнь Бо Ли Цзянь Медисин Ко., Лтд. Соединения пиразола, их фармацевтические композиции и их применение
RU2846204C2 (ru) * 2018-11-30 2025-09-01 Кимера Терапьютикс, Инк. Агенты, разлагающие irak, и их применения
US12497402B2 (en) 2021-02-15 2025-12-16 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
BR112013000868A2 (pt) 2010-07-13 2016-05-17 Hoffmann La Roche derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2688872A4 (en) * 2011-03-22 2014-08-27 Merck Sharp & Dohme AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2013100632A1 (en) * 2011-12-30 2013-07-04 Hanmi Pharm Co., Ltd. THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
RU2637925C2 (ru) 2012-01-10 2017-12-08 Ф. Хоффманн-Ля Рош Аг Соединения тиенопиримидина
AU2013207972B2 (en) * 2012-01-10 2017-06-15 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
WO2014003483A1 (en) * 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
US9216991B2 (en) * 2012-07-10 2015-12-22 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
JP2015528801A (ja) * 2012-07-11 2015-10-01 ニンバス アイリス, インコーポレイテッド Irak阻害剤およびその使用
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
WO2014011911A2 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2016505012A (ja) 2013-01-10 2016-02-18 ニンバス アイリス, インコーポレイテッド Irak阻害剤およびその使用
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
US9200004B2 (en) 2013-01-15 2015-12-01 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
WO2014143242A1 (en) * 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な化合物
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015006181A1 (en) 2013-07-11 2015-01-15 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
PE20160532A1 (es) * 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
CN106232122A (zh) 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途
WO2015085132A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
CA2932353A1 (en) 2013-12-13 2015-06-18 Steven P. Treon Methods to treat lymphoplasmacytic lymphoma
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
BR112016015983A2 (pt) 2014-01-10 2017-08-08 Aurigene Discovery Tech Ltd Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
CA2935887A1 (en) 2014-01-13 2015-07-16 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as irak4 inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
PE20211782A1 (es) 2014-05-23 2021-09-08 Hoffmann La Roche Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
CN107074863B (zh) 2014-06-05 2019-12-03 沃泰克斯药物股份有限公司 Atr激酶抑制剂的制备方法及其不同的固体形式
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
JP6788583B2 (ja) 2014-10-22 2020-11-25 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 増殖性疾患を処置するためのチアゾリル含有化合物
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
SMT202400187T1 (it) 2014-11-06 2024-07-09 Bial R&D Investments S A Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
LT3221306T (lt) * 2014-11-20 2020-03-10 Merck Patent Gmbh Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
EP3268367B8 (en) 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
EP3267996B1 (en) 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
US10040802B2 (en) 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of IRAK4 activity
WO2016144848A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of irak4 activity
EP3268004B1 (en) 2015-03-12 2019-12-18 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of irak4 activity
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR20180025896A (ko) * 2015-07-15 2018-03-09 오리진 디스커버리 테크놀로지스 리미티드 Irak-4 저해제로서 인다졸 및 아자인다졸 화합물
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
CN113620833A (zh) 2015-09-17 2021-11-09 希望之城 Pcna抑制剂
CN105237414B (zh) * 2015-09-30 2017-03-22 浙江永宁药业股份有限公司 ivacaftor中间体及其制备方法和用途
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP6895439B2 (ja) * 2015-12-22 2021-06-30 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft IRAK4調節因子としてのピラゾロ[1,5a]ピリミジン誘導体
SG11201808830YA (en) 2016-04-06 2018-11-29 Lysosomal Therapeutics Inc Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
WO2017192841A1 (en) * 2016-05-04 2017-11-09 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル-アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ[1,2-b]ピリダジン、置換イミダゾ[1,5-b]ピリダジン、関連化合物、および医学的障害の治療におけるその使用
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CN106222183B (zh) * 2016-07-25 2019-11-08 南通大学 靶向人irak1基因的小干扰rna及其应用
JP7059268B2 (ja) 2016-11-02 2022-04-25 エフ.ホフマン-ラ ロシュ アーゲー IRAK4モデュレーターとしてのピラゾロ[1,5a]ピリミジン誘導体
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
AU2018242623B2 (en) 2017-03-31 2024-05-02 Aurigene Oncology Limited Compounds and compositions for treating hematological disorders
CN106946890A (zh) * 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
EP3630766A1 (en) 2017-05-22 2020-04-08 H. Hoffnabb-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
CN111094292A (zh) * 2017-06-21 2020-05-01 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
WO2018234343A1 (en) * 2017-06-21 2018-12-27 F. Hoffmann-La Roche Ag Benzofurans as irak4 modulators
CN110785418A (zh) * 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
WO2019001460A1 (zh) * 2017-06-27 2019-01-03 南京明德新药研发股份有限公司 作为 irak4 抑制剂的稠环化合物
JP7114394B2 (ja) * 2017-08-18 2022-08-08 住友化学株式会社 化合物、レジスト組成物及びレジストパターンの製造方法
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP4624467A2 (en) 2017-09-22 2025-10-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2018359248B2 (en) 2017-10-31 2023-06-01 Curis, Inc. Compounds and compositions for treating hematological disorders
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CN111542529B (zh) * 2017-11-30 2023-06-30 韩美药品株式会社 对蛋白激酶具有抑制活性的噻吩并[3,2-d]嘧啶化合物
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
JP7328987B6 (ja) * 2018-04-05 2023-10-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ii型irak阻害剤としてのヘテロアリール化合物及びその使用
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
BR112021008176A2 (pt) 2018-10-30 2021-08-03 Kronos Bio, Inc. compostos, composições, e métodos para a modulação da atividade da cdk9.
KR102891608B1 (ko) 2018-11-30 2025-11-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
PE20220578A1 (es) * 2019-06-27 2022-04-20 Biogen Ma Inc Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
WO2021066559A1 (en) 2019-10-02 2021-04-08 Kainos Medicine, Inc. N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20230149407A1 (en) 2020-04-04 2023-05-18 Pfizer Inc. Methods of Treating Coronavirus Disease 2019
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
MX2023003698A (es) * 2020-09-30 2023-06-15 Asahi Kasei Pharma Corp Compuesto biciclico que contiene nitrogeno y pirimidina.
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
MX2023009527A (es) 2021-02-15 2023-08-24 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
JP2024516353A (ja) 2021-04-08 2024-04-15 キュリス,インコーポレイテッド がんの治療のための併用療法
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
KR102869914B1 (ko) * 2021-10-28 2025-10-13 재단법인 대구경북첨단의료산업진흥재단 신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
IL312397A (en) 2021-10-29 2024-06-01 Kymera Therapeutics Inc IRAK4 subunits and their synthesis
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012103487A (ru) * 2009-07-02 2013-08-10 Дженентек, Инк. Ингибирующие jak соединения на основе пиразолопиримидина и способы

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436628B1 (en) * 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
EP1434579B1 (en) 2001-10-09 2011-06-08 Amgen Inc. Imidazole derivatives as antiinflammatory agents
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
WO2005004810A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
EP1731494A4 (en) 2004-03-31 2008-03-26 Kuraray Co METHOD FOR PRODUCING A HALOGENATED UNSATURATED CARBONYL COMPOUND
JP2008013527A (ja) 2006-07-10 2008-01-24 Sankyo Co Ltd チエノ[3,2−d]ピリミジン−2,4−ジアミン誘導体
US20080176870A1 (en) * 2006-11-20 2008-07-24 Bert Nolte Heterobicyclic metalloprotease inhibitors
ATE510827T1 (de) * 2007-10-12 2011-06-15 Ingenium Pharmaceuticals Gmbh Inhibitoren von proteinkinasen
JP2012503623A (ja) * 2008-09-24 2012-02-09 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピラゾール化合物
AU2009308675A1 (en) * 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
IT1392824B1 (it) * 2009-02-13 2012-03-23 Sacmi Apparato per formare oggetti
CN101537007A (zh) * 2009-03-18 2009-09-23 中国医学科学院血液病医院(血液学研究所) N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
US20120157439A1 (en) * 2009-08-28 2012-06-21 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
CA2786438C (en) 2010-01-29 2015-10-13 Hanmi Science Co., Ltd. Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
BR112013000868A2 (pt) * 2010-07-13 2016-05-17 Hoffmann La Roche derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012103487A (ru) * 2009-07-02 2013-08-10 Дженентек, Инк. Ингибирующие jak соединения на основе пиразолопиримидина и способы

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAMADA MOHAMED IBRAHIM ET AL, Utility of cyanoacetamides as precursors to pyrazolo[3,4-d]pyrimidin-4-ones, 2-aryl-6-substituted 1,2.3-triazolo[4,5-d]pyrimidines and pyrazolo[1,2-a]pyrimidine-3-carboxamides, Heterocycles, vol. 71, N9, 2007, pp. 1951-1966. *
LIXIN QIAO ET AL, Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors, Bioorganic & Medicinal Chemistry Letters, vol.19, N21, 2009, pp.6122-6126. WO 2009|047359 A1, 16.04.2009. *
WO 2010/034738 A2. *
приоритет 02.07.2009. GEORGE M. BUCKLEY ET AL, IPAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines, Bioorganic & Medicinal Chemistry Letters, vol. 18, N 12, pp.36-3660. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072599B2 (en) 2017-02-01 2021-07-27 Biotheryx, Inc. Pyrazole compounds and uses thereof
RU2761457C2 (ru) * 2017-02-01 2021-12-08 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим Лтд. N1-(4-(5-(циклопропилметил)-1-метил-1h-пиразол-4-ил)пиридин-2-ил)циклогексан-1,4-диаминовые производные и родственные соединения в качестве ингибиторов сk1 и/или irak1 для лечения рака
US11999721B2 (en) 2017-02-01 2024-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pyrazole compounds and uses thereof
RU2770835C1 (ru) * 2018-08-27 2022-04-22 Шэньчжэнь Бо Ли Цзянь Медисин Ко., Лтд. Соединения пиразола, их фармацевтические композиции и их применение
US11958831B2 (en) 2018-08-27 2024-04-16 Artivila (Shenzhen) Innovation Center, Ltd. Pyrazole compounds, pharmaceutical compositions thereof and use thereof
RU2846204C2 (ru) * 2018-11-30 2025-09-01 Кимера Терапьютикс, Инк. Агенты, разлагающие irak, и их применения
US12497402B2 (en) 2021-02-15 2025-12-16 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof

Also Published As

Publication number Publication date
CN105367577A (zh) 2016-03-02
WO2012007375A1 (en) 2012-01-19
AR082154A1 (es) 2012-11-14
EP3252054A1 (en) 2017-12-06
US20180298026A1 (en) 2018-10-18
KR20190077610A (ko) 2019-07-03
CA2802641A1 (en) 2012-01-19
MX358682B (es) 2018-08-31
JP6396376B2 (ja) 2018-09-26
BR112013000868A2 (pt) 2016-05-17
MX340490B (es) 2016-07-11
HK1183029A1 (zh) 2013-12-13
CN105367577B (zh) 2019-04-23
RU2013103539A (ru) 2014-08-20
KR101995013B1 (ko) 2019-07-02
US20120015962A1 (en) 2012-01-19
US9255110B2 (en) 2016-02-09
CN102985426B (zh) 2015-10-07
CA2802641C (en) 2019-03-12
JP2013531018A (ja) 2013-08-01
US20140303149A1 (en) 2014-10-09
EP2593457B1 (en) 2017-08-23
JP2018199703A (ja) 2018-12-20
JP2016222707A (ja) 2016-12-28
CN110003219A (zh) 2019-07-12
US20160207936A1 (en) 2016-07-21
EP2593457A1 (en) 2013-05-22
CN102985426A (zh) 2013-03-20
MX2013000390A (es) 2013-03-08
KR20130132396A (ko) 2013-12-04
US10023589B2 (en) 2018-07-17
JP5985473B2 (ja) 2016-09-06

Similar Documents

Publication Publication Date Title
RU2604062C2 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
US6949560B2 (en) Imidazo-substituted compounds as p38 kinase inhibitors
EP1228070B1 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
TWI617560B (zh) PI3Kδ 抑制劑以及其應用和生產方法
US7456185B2 (en) Substituted quinazoline compounds useful as p38 kinase inhibitors
WO2008068171A9 (en) Substituted pyrimidines and their use as jnk modulators
WO2023186069A1 (zh) 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途
RU2378275C2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-c]ПИРИДИНА И СПОСОБ ИХ ПОЛУЧЕНИЯ
CN116903613A (zh) 2-氧代喹唑啉并五元杂环衍生物、其制备方法及其应用
US5466706A (en) 9H-imidazo[1,2-A]benzimidazole-3-acetamide derivatives, their preparation and their therapeutic application
CA2799817A1 (en) Inhibitors of jnk
EP2576537B1 (en) 2-amino-pyrimidine derivatives useful as inhibitors of jnk
CN116836162A (zh) 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用
HK1183029B (en) Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
TR201908937T4 (tr) P38 MAP kinazı inhibe eden indanil üre bileşikleri.
TW201217379A (en) Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
CN119431402A (zh) 噻唑并环类化合物及其应用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200709